SG11202103282YA - Small molecule mdm2 protein degraders - Google Patents
Small molecule mdm2 protein degradersInfo
- Publication number
- SG11202103282YA SG11202103282YA SG11202103282YA SG11202103282YA SG11202103282YA SG 11202103282Y A SG11202103282Y A SG 11202103282YA SG 11202103282Y A SG11202103282Y A SG 11202103282YA SG 11202103282Y A SG11202103282Y A SG 11202103282YA SG 11202103282Y A SG11202103282Y A SG 11202103282YA
- Authority
- SG
- Singapore
- Prior art keywords
- small molecule
- mdm2 protein
- molecule mdm2
- protein degraders
- degraders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742627P | 2018-10-08 | 2018-10-08 | |
| PCT/US2019/054913 WO2020076660A1 (en) | 2018-10-08 | 2019-10-07 | Small molecule mdm2 protein degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103282YA true SG11202103282YA (en) | 2021-04-29 |
Family
ID=68343478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103282YA SG11202103282YA (en) | 2018-10-08 | 2019-10-07 | Small molecule mdm2 protein degraders |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11046703B2 (en) |
| EP (1) | EP3863720A1 (en) |
| JP (1) | JP2022504541A (en) |
| KR (1) | KR20210072043A (en) |
| CN (1) | CN112912143A (en) |
| AU (1) | AU2019356772A1 (en) |
| BR (1) | BR112021006647A2 (en) |
| CA (1) | CA3112591A1 (en) |
| IL (1) | IL281719B (en) |
| MX (1) | MX2021003999A (en) |
| SG (1) | SG11202103282YA (en) |
| WO (1) | WO2020076660A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112912143A (en) * | 2018-10-08 | 2021-06-04 | 美国密歇根州立大学试剂中心 | Small molecule MDM2 protein degradation agent |
| TW202124374A (en) | 2019-09-13 | 2021-07-01 | 美商拜歐斯瑞克斯公司 | Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| CN114853731A (en) * | 2021-02-04 | 2022-08-05 | 上海长森药业有限公司 | Difunctional MDM2 protein degrading agent, and preparation method, pharmaceutical composition and application thereof |
| WO2023036974A1 (en) | 2021-09-13 | 2023-03-16 | Astrazeneca Ab | Spirocyclic compounds |
| US20230233546A1 (en) * | 2021-12-15 | 2023-07-27 | Kymera Therapeutics, Inc. | Methods of treating cancer |
| TW202404588A (en) * | 2022-06-06 | 2024-02-01 | 美商凱麥拉醫療公司 | Mdm2 degraders and uses thereof |
| WO2024078370A1 (en) * | 2022-10-13 | 2024-04-18 | 中国科学院上海药物研究所 | Small molecular compound having substituted phenylspiro[indoline-3,3'-pyrrolidine] structure |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57501692A (en) | 1980-09-24 | 1982-09-16 | ||
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| DE3381518D1 (en) | 1982-01-22 | 1990-06-07 | Cetus Corp | METHOD FOR CHARACTERIZING HLA AND THE CDNS TEST AGENTS USED IN IT. |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US7083983B2 (en) | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
| US6831155B2 (en) | 1999-12-08 | 2004-12-14 | President And Fellows Of Harvard College | Inhibition of p53 degradation |
| DE60227108D1 (en) | 2001-12-18 | 2008-07-24 | Hoffmann La Roche | CIS-IMIDAZOLINE AS MDM2 HEMMER |
| ES2301717T3 (en) | 2001-12-18 | 2008-07-01 | F. Hoffmann-La Roche Ag | CIS-2,4,5-TRIFENIL-IMIDAZOLINAS AND ITS USE FOR TUMOR TREATMENT. |
| AU2003243594A1 (en) | 2002-06-13 | 2003-12-31 | Johns Hopkins University | Novel boronic chalcone derivatives and uses thereof |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| EP1633749A4 (en) | 2003-02-13 | 2011-03-02 | Us Gov Health & Human Serv | Deazaflavin compounds and methods of use thereof |
| US6916833B2 (en) | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
| US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| US7829742B2 (en) | 2003-12-22 | 2010-11-09 | Johns Hopkins University | Boronic acid aryl analogs |
| US8598127B2 (en) | 2004-04-06 | 2013-12-03 | Korea Research Institute Of Bioscience & Biotechnology | Peptides for inhibiting MDM2 function |
| JP4814228B2 (en) | 2004-05-18 | 2011-11-16 | エフ．ホフマン−ラ ロシュ アーゲー | New CIS-imidazoline |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| NZ561215A (en) | 2005-02-22 | 2010-12-24 | Univ Michigan | Small molecule inhibitors of MDM2 and uses thereof |
| MX2007011151A (en) | 2005-03-16 | 2007-10-17 | Hoffmann La Roche | Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments. |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| US7495007B2 (en) | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US7737174B2 (en) | 2006-08-30 | 2010-06-15 | The Regents Of The University Of Michigan | Indole inhibitors of MDM2 and the uses thereof |
| US7638548B2 (en) | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| WO2008072655A1 (en) | 2006-12-14 | 2008-06-19 | Daiichi Sankyo Company, Limited | Imidazothiazole derivatives |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| US7553833B2 (en) | 2007-05-17 | 2009-06-30 | Hoffmann-La Roche Inc. | 3,3-spiroindolinone derivatives |
| WO2011060049A2 (en) | 2009-11-12 | 2011-05-19 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
| UA109464C2 (en) | 2010-11-12 | 2015-08-25 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Spiro-oxindoles as mdm2 antagonists |
| CA2835422C (en) * | 2011-05-11 | 2016-10-11 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| WO2014082083A1 (en) | 2012-11-26 | 2014-05-30 | Caris Science, Inc. | Biomarker compositions and methods |
| BR112017019751A2 (en) * | 2015-03-18 | 2018-05-29 | Arvinas Inc | bifunctional compound, pharmaceutical composition, and methods for treating or preventing a disease or disorder, and for degrading a target protein in a cell |
| CN113788818A (en) * | 2016-04-06 | 2021-12-14 | 密执安大学评议会 | MDM2 protein degrading agent |
| EP3440082A1 (en) * | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| US11541051B2 (en) * | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| CN112912143A (en) * | 2018-10-08 | 2021-06-04 | 美国密歇根州立大学试剂中心 | Small molecule MDM2 protein degradation agent |
-
2019
- 2019-10-07 CN CN201980066182.3A patent/CN112912143A/en active Pending
- 2019-10-07 BR BR112021006647-0A patent/BR112021006647A2/en not_active Application Discontinuation
- 2019-10-07 MX MX2021003999A patent/MX2021003999A/en unknown
- 2019-10-07 WO PCT/US2019/054913 patent/WO2020076660A1/en active Application Filing
- 2019-10-07 EP EP19794325.1A patent/EP3863720A1/en not_active Withdrawn
- 2019-10-07 US US16/594,344 patent/US11046703B2/en active Active
- 2019-10-07 SG SG11202103282YA patent/SG11202103282YA/en unknown
- 2019-10-07 KR KR1020217013489A patent/KR20210072043A/en unknown
- 2019-10-07 AU AU2019356772A patent/AU2019356772A1/en not_active Abandoned
- 2019-10-07 JP JP2021519603A patent/JP2022504541A/en active Pending
- 2019-10-07 CA CA3112591A patent/CA3112591A1/en active Pending
-
2021
- 2021-03-22 IL IL281719A patent/IL281719B/en unknown
- 2021-06-09 US US17/342,974 patent/US20210309666A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210309666A1 (en) | 2021-10-07 |
| CA3112591A1 (en) | 2020-04-16 |
| JP2022504541A (en) | 2022-01-13 |
| WO2020076660A1 (en) | 2020-04-16 |
| CN112912143A (en) | 2021-06-04 |
| AU2019356772A1 (en) | 2021-04-01 |
| MX2021003999A (en) | 2021-06-23 |
| US20200109149A1 (en) | 2020-04-09 |
| EP3863720A1 (en) | 2021-08-18 |
| IL281719B (en) | 2022-06-01 |
| BR112021006647A2 (en) | 2021-07-13 |
| IL281719A (en) | 2021-05-31 |
| KR20210072043A (en) | 2021-06-16 |
| US11046703B2 (en) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201806968B (en) | Mdm2 protein degraders | |
| SG11202103282YA (en) | Small molecule mdm2 protein degraders | |
| SG11202003754YA (en) | High concentration protein formulations with reduced viscosity | |
| IL281804A (en) | Protein purification methods | |
| HK1247933A1 (en) | Fusion protein containing bdnf | |
| DK3737402T3 (en) | Modificeret protein | |
| EP3723757A4 (en) | Small molecule degraders that recruit dcaft15 | |
| IL261040B (en) | Protein purification | |
| GB201711481D0 (en) | Protein purification | |
| IL279355A (en) | Anti-steap1 antigen-binding protein | |
| IL283229A (en) | High concentration protein formulation | |
| ZA202102533B (en) | Fusion protein | |
| SG11202006140TA (en) | Process for providing pegylated protein composition | |
| GB2558968B (en) | G Proteins | |
| EP3428180A4 (en) | Fluorescent protein | |
| IL284006A (en) | Mitochondria-targeting peptides | |
| EP3649159C0 (en) | Fusion protein | |
| GB201712792D0 (en) | Fusion protein | |
| GB201909710D0 (en) | Proteins | |
| GB201813737D0 (en) | Peptide exchange protein | |
| GB201801323D0 (en) | Peptide exchange protein | |
| GB201814440D0 (en) | Peptide | |
| SG11202005990RA (en) | Process for providing pegylated protein composition | |
| SG11202005952TA (en) | Process for providing pegylated protein composition | |
| GB201803074D0 (en) | Peptide |